By treating weight management as a collaborative, medically guided journey, patients are better prepared to adapt their treatment plans as new scientific advancements become available
The FDA doesn't approve compounded medications prepared under 503A frameworks - it approves the active pharmaceutical ingredients and it oversees the pharmacies through state board regulation, but the finished compounded product itself doesn't go through the same approval process as Wegovy or Mounjaro
Weight loss is a significant consideration for both medications, especially given the obesity epidemic and its association with conditions like Type 2 Diabetes
AnholmCKumarathuraiPSamkaniAPedersenLRBostonRCNielsenOWet alEffect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: a randomized trial
The STEP 1 extension study found that participants who stopped semaglutide regained approximately two-thirds of their previously lost weight within one year
Despite its rarity, lipodystrophy represents a serious medical issue because it can interfere with drug uptake while also causing aesthetic problems [45]
